Compare Stocks: BIVI, ESLA, QNCX, and BYSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIVI BioVie	$1.40	$1.69	$0.82 ▼ $3.79	$10.56M	0.6	7.62 million shs	2.04 million shs
BYSI BeyondSpring	$0.84	$1.38	$0.73 ▼ $2.44	$34.50M	0.48	2.02 million shs	777,182 shs
ESLA Estrella Immunopharma	$0.72	$0.88	$0.68 ▼ $3.15	$31.12M	0.88	26,823 shs	9,010 shs
QNCX Quince Therapeutics	$34.04	$21.01	$15.10 ▼ $909.98	$34.72M	1.36	35,154 shs	26,046 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIVI BioVie	0.00%	+40.10%	-22.22%	+2.94%	-15.15%
BYSI BeyondSpring	0.00%	-3.55%	-34.95%	-39.85%	-58.46%
ESLA Estrella Immunopharma	0.00%	+0.08%	-13.90%	-35.43%	-19.47%
QNCX Quince Therapeutics	0.00%	+12.72%	+80.30%	+71.09%	-89.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIVI BioVie	$1.40	$1.69	$0.82 ▼ $3.79	$10.56M	0.6	7.62 million shs	2.04 million shs
BYSI BeyondSpring	$0.84	$1.38	$0.73 ▼ $2.44	$34.50M	0.48	2.02 million shs	777,182 shs
ESLA Estrella Immunopharma	$0.72	$0.88	$0.68 ▼ $3.15	$31.12M	0.88	26,823 shs	9,010 shs
QNCX Quince Therapeutics	$34.04	$21.01	$15.10 ▼ $909.98	$34.72M	1.36	35,154 shs	26,046 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIVI BioVie	0.00%	+40.10%	-22.22%	+2.94%	-15.15%
BYSI BeyondSpring	0.00%	-3.55%	-34.95%	-39.85%	-58.46%
ESLA Estrella Immunopharma	0.00%	+0.08%	-13.90%	-35.43%	-19.47%
QNCX Quince Therapeutics	0.00%	+12.72%	+80.30%	+71.09%	-89.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIVI BioVie	1.00	Sell	N/A	N/A
BYSI BeyondSpring	1.00	Sell	N/A	N/A
ESLA Estrella Immunopharma	2.00	Hold	$8.00	1,006.19% Upside
QNCX Quince Therapeutics	2.27	Hold	$310.50	812.16% Upside

Current Analyst Ratings Breakdown

Latest BIVI, ESLA, QNCX, and BYSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00
7/21/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	BIVI BioVie	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	QNCX Quince Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/24/2026	QNCX Quince Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$80.00
6/23/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$80.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIVI BioVie	N/A	N/A	N/A	N/A	$1.36 per share	N/A
BYSI BeyondSpring	$1.75M	19.72	$0.11 per share	7.38	($0.59) per share	-1.42
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.27) per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIVI BioVie	-$22.07M	-$3.15	N/A	N/A	N/A	N/A	-126.02%	-108.88%	8/24/2026 (Estimated)
BYSI BeyondSpring	-$1.01M	-$0.14	N/A	N/A	N/A	N/A	N/A	-25.95%	N/A
ESLA Estrella Immunopharma	-$13.06M	-$0.24	N/A	N/A	N/A	N/A	N/A	-328.72%	9/2/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-154.49%	N/A

Latest BIVI, ESLA, QNCX, and BYSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	N/A	ESLA Estrella Immunopharma	-$0.09	N/A	N/A	N/A	N/A	N/A
8/24/2026	Q4 2026	BIVI BioVie	-$0.52	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	BYSI BeyondSpring	-$0.54	-$0.02	+$0.52	-$0.02	$8.77 million	N/A
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/13/2026	Q2 2026	ESLA Estrella Immunopharma	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A
8/12/2026	Q4 2026	BIVI BioVie	-$0.52	-$0.70	-$0.18	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIVI BioVie	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIVI BioVie	N/A	3.59	3.59
BYSI BeyondSpring	N/A	1.09	1.09
ESLA Estrella Immunopharma	N/A	0.20	0.20
QNCX Quince Therapeutics	N/A	2.92	2.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIVI BioVie	4.59%
BYSI BeyondSpring	40.29%
ESLA Estrella Immunopharma	0.35%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
BIVI BioVie	0.90%
BYSI BeyondSpring	29.31%
ESLA Estrella Immunopharma	5.80%
QNCX Quince Therapeutics	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIVI BioVie	10	7.54 million	7.48 million	No Data
BYSI BeyondSpring	80	41.12 million	29.07 million	Optionable
ESLA Estrella Immunopharma	N/A	43.03 million	40.54 million	Not Optionable
QNCX Quince Therapeutics	60	1.02 million	945,000	Optionable

BIVI, ESLA, QNCX, and BYSI Headlines

Recent News About These Companies

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14 at 8:00 AM | globenewswire.com

Quince Therapeutics (QNCX) Projected to Announce Earnings on Tuesday

August 9, 2026 | americanbankingnews.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

May 24, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

May 18, 2026 | seekingalpha.com

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026 | globenewswire.com

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60

May 15, 2026 | msn.com

Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80

April 28, 2026 | msn.com

Quince Therapeutics Delays Annual 10-K Filing

April 27, 2026 | theglobeandmail.com

Quince Therapeutics settles $16.4M debt with $5.5M payment

March 30, 2026 | msn.com

Why did QNCX stock surge 40% in pre-market today?

March 30, 2026 | msn.com

Quince Therapeutics Settles Approximately $16.4 Million of Debt

March 30, 2026 | businesswire.com

Bankruptcy threat looms as Quince runs out of options

February 13, 2026 | pharmaphorum.comP

Quince Therapeutics stock plummets after revealing strategic alternatives

February 13, 2026 | au.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BIVI, ESLA, QNCX, and BYSI Company Descriptions

BioVie NASDAQ:BIVI

$1.40 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.27 -0.13 (-9.00%)

As of 08/14/2026 07:59 PM Eastern

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BeyondSpring NASDAQ:BYSI

$0.84 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.82 -0.02 (-2.04%)

As of 08/14/2026 07:50 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Estrella Immunopharma NASDAQ:ESLA

$0.72 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.74 +0.02 (+2.18%)

As of 08/14/2026 07:52 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Quince Therapeutics NASDAQ:QNCX

$34.04 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$33.60 -0.44 (-1.29%)

As of 08/14/2026 07:56 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIVI, ESLA, QNCX, and BYSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIVI, ESLA, QNCX, and BYSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIVI, ESLA, QNCX, and BYSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BIVI, ESLA, QNCX, and BYSI Company Descriptions

BioVie NASDAQ:BIVI

BeyondSpring NASDAQ:BYSI

Estrella Immunopharma NASDAQ:ESLA

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIVI, ESLA, QNCX, and BYSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIVI, ESLA, QNCX, and BYSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIVI, ESLA, QNCX, and BYSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BIVI, ESLA, QNCX, and BYSI Company Descriptions

BioVie NASDAQ:BIVI

BeyondSpring NASDAQ:BYSI

Estrella Immunopharma NASDAQ:ESLA

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools